# Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients

> **NCT04581967** · — · UNKNOWN · sponsor: **Damanhour University** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer Patients

## Interventions

- **GENETIC:** polymorphism analysis
- **DRUG:** Doxorubicin-Cyclophosphamide regimen

## Key facts

- **NCT ID:** NCT04581967
- **Lead sponsor:** Damanhour University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-15
- **Primary completion:** 2020-12-15
- **Final completion:** 2021-01-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-10-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04581967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04581967, "Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04581967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*